Real-World data on efficacy of L-glutamine in preventing sickle cell disease-related complications in pediatric and adult patients.

ABSTRACT:

Background

L-glutamine has been shown to play an important role in the regulation of oxidative stress which is one of the key contributors to the pathophysiology of sickle cell disease (SCD). In a Phase 3 clinical trial, L-glutamine demonstrated a significant reduction in SCD-related complications including vaso-occlusive crises (VOCs), hospitalizations, and acute chest syndrome (ACS) compared to placebo in patients with SCD.

Objective

The primary objective was to confirm the efficacy of L-glutamine (Endari^®) therapy in pediatric and adult patients with SCD at follow-up time points of 24, 48 and 72 weeks.

Methods

In the observational study, nineteen patients with SCD were treated orally with L-glutamine twice daily for 72 weeks. Clinical and laboratory para

SUBMITTER: Elenga N 

PROVIDER: S-EPMC9376442 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature